Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14756447 | 0.82 | ALDH1A1 (0.43) | HPGDKDM4EL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL878777 | 0.80 | POLB (0.46) | HPGDKDM4EL3MBTL1ALDH1A1EPHX1 | |
| SCHEMBL21017090 | 0.80 | HPGD (0.48) | HPGDKDM4EL3MBTL1ALDH1A1EPHX1 | |
| SCHEMBL19559003 | 0.80 | KDM4E (0.50) | HPGDKDM4EL3MBTL1ALDH1A1EPHX1 | |
| SCHEMBL12335919 | 0.80 | HPGD (0.48) | HPGDKDM4EL3MBTL1ALDH1A1EPHX1 | |
| SCHEMBL24925914 | 0.80 | HPGD (0.48) | HPGDKDM4EL3MBTL1ALDH1A1EPHX1 | |
| SCHEMBL13753136 | 0.80 | ALDH1A1 (0.42) | HPGDKDM4EL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL5940258 | 0.80 | ALDH1A1 (0.42) | HPGDKDM4EL3MBTL1ALDH1A1KMT2A | |
| SCHEMBL14302929 | 0.80 | MEN1 (0.46) | HPGDKDM4EL3MBTL1ALDH1A1EPHX1 | |
| SCHEMBL8435313 | 0.80 | HPGD (0.48) | HPGDKDM4EL3MBTL1ALDH1A1EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11679066-B2 | Dissolvable solid fibrous articles containing anionic surfactants | THE PROCTER & GAMBLE COMPANY (US) | 2023-06-20 | — | — | US | disclosed |
| WO-2023056069-A1 | DEGRADER-ANTIBODY CONJUGATES AND METHODS OF USING SAME | ANGIEX, INC. (US) | 2023-04-06 | — | — | WO | disclosed |
| US-11523979-B2 | Personal care composition preservatives level optimization | THE PROCTER & GAMBLE COMPANY (US) | 2022-12-13 | — | — | US | disclosed |
| US-11318073-B2 | Low surfactant aerosol antidandruff composition | THE PROCTER AND GAMBLE COMPANY (US) | 2022-05-03 | — | — | US | disclosed |
| US-20210253303-A1 | BOTTLE ADAPTED FOR STORING A LIQUID COMPOSITION WITH AN AESTHETIC DESIGN SUSPENDED THEREIN | THE PROCTER & GAMBLE COMPANY | 2021-08-19 | — | — | US | disclosed |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-05-11 | — | — | US | disclosed |
| US-20210121378-A1 | PERSONAL CARE COMPOSITION PRESERVATIVES LEVEL OPTIMIZATION | THE PROCTER & GAMBLE COMPANY | 2021-04-29 | — | — | US | disclosed |
| US-20210045979-A1 | METHOD OF MAKING A CLEAR PERSONAL CARE COMPRISING MICROCAPSULES | THE PROCTER & GAMBLE COMPANY | 2021-02-18 | — | — | US | disclosed |
| US-10881597-B2 | Compositions with scalp health agents with increased deposition | THE PROCTER AND GAMBLE COMPANY (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200405587-A1 | DISSOLVABLE SOLID FIBROUS ARTICLES CONTAINING ANIONIC SURFACTANTS | THE PROCTER & GAMBLE COMPANY | 2020-12-31 | — | — | US | disclosed |
| US-20120178021-A1 | RESIN AND PHOTORESIST COMPOSITION COMPRISING THE SAME | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2012-07-12 | — | — | US | disclosed |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | NOVARTIS AG (CH) | 2011-05-26 | — | — | US | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-7902375-B2 | Antiallergens; antiarthritic agents; psoriasis; inflammatory bowel disorders; Crohn's disease; sepsis ; antiproliferative agents; anticancer agents; transplant rejection; stroke; antidiabetic agents; restenosis | NOVARTIS AG (CH) | 2011-03-08 | — | — | US | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | NOVARTIS AG (CH) | 2008-11-13 | — | — | US | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210045979-A1 | METHOD OF MAKING A CLEAR PERSONAL CARE COMPRISING MICROCAPSULES | AQP1, AQP3, IL33 | HPGD 3682/4885KDM4E 4384/4885L3MBTL1 3529/4885 |
| US-10881597-B2 | Compositions with scalp health agents with increased deposition | POLR1C, CHIT1, PPHLN1 | HPGD 2210/4885KDM4E 3079/4885L3MBTL1 4710/4885 |
| US-20200405587-A1 | DISSOLVABLE SOLID FIBROUS ARTICLES CONTAINING ANIONIC SURFACTANTS | MFAP1, SGMS2, DSP | HPGD 3034/4885KDM4E 3398/4885L3MBTL1 3780/4885 |
| US-20090326058-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | HPGD 3879/4885KDM4E 3721/4885L3MBTL1 4402/4885 |
| US-20110124693-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK1 | HPGD 2745/4885KDM4E 458/4885L3MBTL1 4003/4885 |
| US-20110124624-A1 | 5-PHENYL-4-METHYL-THIAZOL-2-YL-AMINE DERIVATIVES AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3 KINASE ENZYMES (PI3) FOR THE TREATMENT OF INFLAMMATORY DISEASES | PIK3CA, JAK2, JAK3 | HPGD 2619/4885KDM4E 471/4885L3MBTL1 3976/4885 |
| US-20080280871-A1 | 5-Phenyl-4-Methyl-Thiazol-2-Yl-Amine Derivatives as Inhibitors of Phosphatidylin Ositol 3 Kinase Enzymes (PI13) For Treatment of Inflammatory Diseases | PI4KA, IP6K3, PHOSPHO1 | HPGD 3839/4885KDM4E 817/4885L3MBTL1 3493/4885 |
| US-11318073-B2 | Low surfactant aerosol antidandruff composition | SMURF1, ANXA1, ANXA3 | HPGD 4055/4885KDM4E 4853/4885L3MBTL1 4174/4885 |
| US-20120178021-A1 | RESIN AND PHOTORESIST COMPOSITION COMPRISING THE SAME | SULT1A1, SULT1E1, C1S | HPGD 1860/4885KDM4E 591/4885L3MBTL1 1982/4885 |
| US-11523979-B2 | Personal care composition preservatives level optimization | POLR1C, CUTA, MSH6 | HPGD 2100/4885KDM4E 1860/4885L3MBTL1 4186/4885 |
| US-20080255042-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | HPGD 3879/4885KDM4E 3721/4885L3MBTL1 4402/4885 |
| US-11679066-B2 | Dissolvable solid fibrous articles containing anionic surfactants | MFAP1, SGMS2, DSP | HPGD 3034/4885KDM4E 3398/4885L3MBTL1 3780/4885 |
| US-11001575-B1 | Benzolactam compounds as protein kinase inhibitors | MAPK1, ALK, MAP3K1 | HPGD 3780/4885KDM4E 1086/4885L3MBTL1 612/4885 |
| US-20210121378-A1 | PERSONAL CARE COMPOSITION PRESERVATIVES LEVEL OPTIMIZATION | POLR1C, CUTA, MSH6 | HPGD 2100/4885KDM4E 1860/4885L3MBTL1 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.